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Abstract.  It has previously been shown that efficient 
export of U1  snRNA or of microinjected, in vitro syn- 
thesized, RNA transcripts from the nucleus of Xeno- 
pus oocytes is facilitated by their monomethyl guano- 
sine cap structures. Nuclear exit of these transcripts 
could be competitively inhibited by microinjection of 
an excess  of a cap analog, the dinucleotide mTGpppG 
(Hamm, J., and I. W. Mattaj. 1990. Cell.  63:109-118). 
We have now analyzed the ability of several  other 
related cap analogs to inhibit the export of U1  snRNA 
from the nucleus. The results define the recognition 
specificity of a factor(s) involved in RNA transport, 
and indicate that the cap binding activity (CBA) in- 
volved in RNA export is different from cap binding 
proteins (CBPs) involved in the initiation of transla- 
tion. A CBP,  whose specificity for different analogs 
correlates with the ability of the analogs to inhibit U1 
snRNA export, is identified in nuclear extracts pre- 
pared from HeLa cells. We propose that this protein 
may have a role in the export of capped RNAs from 
the nucleus. 
T 
He. mechanism of nuclear export of RNAs transcribed 
by RNA polymerase II (U snRNAs and mRNAs) is 
not well understood.  However, recent progress in this 
area has been significant. Sequences and structural features 
of RNAs which are either required for export or which result 
in nuclear retention have been identified (for recent reviews 
see Maquat,  1991; Izaurralde and Mattaj, 1992). These are 
presumed to interact with components of the transport ma- 
chinery or with anchoring nuclear factors, respectively. Sev- 
eral of  the pre-mRNA sequences that affect transport are also 
required for RNA processing events. 
Direct evidence for the role of introns in the nuclear reten- 
tion of pre-mRNAs came from a series of experiments per- 
formed in yeast (Legrain and Rosbash,  1989), mammalian 
cultured ceils (Chang and Sharp, 1989) or Xenopus oocytes 
(Hamm and Mattaj, 1990). Mutated pre-mRNAs that could 
not be spliced but that could form defective splicing com- 
plexes were anchored in the nucleus, presumably in abortive 
complexes. Conversely, mutant pre-mRNAs unable to form 
detectable splicing complexes were exported rapidly into the 
cytoplasm.  Thus the formation of splicing complexes and 
RNA export from the nucleus are antagonistic, or compet- 
ing, processes. 
The effect of 3' end processing  on the export of several 
RNA  transcripts  has  also  been  analyzed (Eckner  et al., 
1991). In contrast to the situation with intron splicing, evi- 
dence for a positive mechanistic linkage between 3' end for- 
mation and the export of histone mRNA transcripts was ob- 
tained.  Moreover,  at  least  for  histone  mRNAs,  specific 
recognition of sequences or structures within the processed 
RNA seemed also to be required for export from the nucleus 
(Eckner et al.,  1991). 
Sequence or structural  features are limited to particular 
RNAs or to subclasses of RNA, thus they cannot be signals 
involved in the transport of all RNAs. One of the structural 
features common to all polymerase II-transcribed RNAs, 
and thus a good candidate for recognition by factors gener- 
ally involved in export of these RNAs, is the monomethyl 
guanosine cap structure mVG(5')ppp(5')N. Indeed, it has re- 
cently been shown that efficient export of both U1 RNA and 
microinjected, in vitro synthesized, RNAs from the nucleus 
of  Xenopus  oocytes  is  dependent  on  their  having  an 
mTGpppN cap  structure.  Furthermore,  nuclear  exit of U1 
snRNA transcripts is specifically inhibited by microinjection 
of an excess of a cap  analog,  the dinucleotide  m7GpppG 
(Hamm and Mattaj,  1990). 
These results imply the existence of a cap binding activity 
(CBA) ~  involved in export of UI snRNA, and probably also 
of other pol II-transcribed  RNAs, that binds directly to the 
monomethyl  cap  structure.  Several cap  binding  proteins 
(CBPs), present either in the cytoplasm or in the nucleus, 
have previously  been  described  (Sonenberg  et al.,  1978; 
Sonenberg, 1981; Patzelt et al., 1983; Rozen and Sonenberg, 
1987; Ohno et al., 1990), the best studied being the eukary- 
otic translation initiation factor 4E (elF-4E; for reviews see 
Shatkin,  1985; Rhoads,  1988; Sonenberg,  1988). In this 
study we have examined whether any of these CBPs might 
1. Abbreviations  used in this paper: CBA, cap binding activity; CBP, cap 
binding protein. 
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specificity for different cap analogs correlates well with the 
ability  of  the  analogs  to  inhibit  131  snRNA  export  was 
identified in nuclear extracts  from HeLa cells. Analysis of 
the  biochemical  properties  and  cap-binding  specificity  of 
this protein suggests strongly that it is the CBP previously 
identified and purified by Ohno et al. (1990). The properties 
of this protein are consistent with it being an effector of nu- 
clear export. 
Materials and Methods 
Materials 
T3  RNA polymerase and RNasin were from Promega Biotec (Madison, 
WI). BSA (fraction V), Calf Intestine Alkaline Phosphatase (type I), and 
Ferritin  from Horse Spleen (type I) were from Sigma Chemical Co. (St. 
Louis, MO). Pepstatin A, benzamidine and DTT were from Sigma Chemi- 
cal Co., PMSF from Serva Biochemicals (Pararnus, NJ), Trasyiol (10,000 
KIE/ml) from Bayer and thiodyglycol from Pierce Chemical Co. (Rockford, 
IL).  Ammonium  sulfate  (nuelease  and  protease  free)  was from Sigma 
Chemical Co.  All column chromatography  resins were from Pharmaeia 
Fine Chemicals (Piscataway, NJ). Triton X-100, Tween 20, and polyethyl- 
ene glycol (PEG 4000) were from Merck & Co. (Rahway,  NJ). The cap ana- 
logs mTGpppG and GpppG were purchased  from Boehringer Mannheim 
GmbH (Mannheim, Germany) and Sigma Chemical Co. respectively, GDP 
was from Sigma Chemical Co. EtTGpppG, m2.TGpppG, mTGMP, mTGDP 
and mTGTP were synthesized and purified as described (Darzynkiewicz et 
ai., 1985, 1988, 1989, 1990). Labeled nucleoside triphosphates were from 
Amersham Corp (Arlington Heights, IL). 
Recombinant Plasmids and In Vitro Synthesis of 
RNA Transcripts 
The UIAD mutant was described by Harem et ai., 1987. For native gel as- 
says, a 77-nucleotide RNA fragment was used. This fragment was obtained 
by in vitro transcription of plasmid U1SII- (Scherly et ai.,  1989) using T3 
RNA polymerase. The in vitro transcription reactions were performed ac- 
cording to the manufacturer (Promega-Biotec) and included the incorpora- 
tion of (~-32P)UTP and, as indicated, a cap analog. Unlabeled competitor 
RNA was synthesized as described above with the following modifications. 
The reaction volume was increased to 800 #1, and incubation was performed 
for 3 h. No cap analog was included in the reaction. All RNA products were 
phenol  extracted  and  purified by gel  filtration  on Sephadex G-50  spin 
columns equilibrated with 10 mM Tris-HC1, pH 8.0 and 1 mM EDTA. Un- 
labeled RNAs were concentrated by ethanol precipitation  and quantified 
spectrophotometricaily. Labeled RNAs were further purified by electropho- 
resis on an 8% denaturing polyacrylarnide gel, the RNA was localized by 
autoradiography, excised from the gel, and eluted overnight at room temper- 
ature in 0.5 M Tris-HC1, pH 7.4, 1 mM MgCI2, 0.1% SDS (wt/vol), 0,1 
mM EDTA and  10 ~g mi-z of yeast RNA.  The eluted RNA was ethanol 
precipitated and resuspended in H20 at 2  ￿  104 cpm ~1-1. The integrity 
of the transcribed  products was examined by analysis on denaturing 6% 
polyacrylarnide gels. Yeast RNA (Sigma Chemical Co.), (type XI; further 
purified by phenol extraction) was used as an unlabeled competitor. 
Oocyte Injections 
Oocyte  injections  were  performed  as  described  by  Harem  and  Mattaj 
(1990). To transcribe U1AD  RNA 20 nl of  a solution of  the plasmid carrying 
the corresponding gene was microinjected into oocyte nuclei. The concen- 
tration of microinjected DNA was 250 t~g mi-t. After a 16-h incubation at 
20oc,  (t~-32P)GTP and cap analogs were coinjected into oocyte cytoplasms. 
The preinjection of DNA templates was carried out to allow the assembly 
of transcription complexes, and thus to prevent any delay in labeling of the 
transcripts whose transport was being studied. Cap analogs were dissolved 
in H20 and injected at a final concentration of 10 or 50 mM together with 
0.25/~Ci #1  -l of (a-32p)GTP (specific activity 400 Ci mmole-l). The vol- 
ume microinjected was 20 nl. After four additional hours oocytes were dis- 
sected and analyzed as described by Harem and Mattaj (1990). 
Electrophoretic Mobility Retardation Assay 
Binding reactions were carried out in BB buffer (10 mM potassium phos- 
phate, pH 8.0, 0.25 M KCI, 2 mM EDTA, and 5% glycerol). All samples 
contained 8 t~g of yeast RNA (with the exception of samples shown in Fig. 
3 A),  1 U/#I -z of RNasin and '~4  ￿  104 cpm of the radiolabeled RNA 
fragments described above. Final sample volumes were 10 ~1. Nuclear ex- 
tracts or fractions were added to the reaction mixtures from a diluted stock 
solution in the same buffer. After 30 min at 25~  3/~1 of Sample Buffer 
(20% glycerol and 0.05% bromopbenol blue in BB buffer) was added to 
each sample. Samples were applied to a 6% nondenaturing polyacrylamide 
gel (29:1, acryl/bisacryl ratio). Electrophoresis was carried out at a constant 
voltage of 10 V cm  -1 at room temperature in TBE buffer. Gels were fixed 
in 10 % acetic acid before drying. Complexes were visualized by autorading- 
raphy. 
SDS-PAGE 
Protein gels were  carried  out according  to Laemmli  (1970). Gels  were 
stained with Coomassie brillant blue R or with silver nitrate.  Molecular 
mass standards used were the Sigma Chemical Co., MW-SDS-200, kit com- 
posed of: Rabbit Muscle Myosin (205 kD),  Escherichia coil fl-gaiactosi- 
dase (116 kD),  Rabbit Muscle Phosphorylase b (97 kD),  BSA (66 kD), 
Ovaibumin (45 kD), and Bovine Erythrocyte Carbonic Anhydrase (29 kD). 
HeLa Nuclear Extract 
HeLa  nuclear  extracts  were prepared  from ~10 z~ cells as described by 
Dignam et al. (1983) with the following modifications. Buffer C contained 
0.6 M KC1 instead of  0.42 M NaCI and 0.05% Tween 20, 300 ~g ml  -z ben- 
zamidine, 2  /~g ml  -~ pepstatin  A, 0.5% (vol/vol) thiodyglycol, and  1% 
(vol/vol) Trasylol. Protease inhibitors and DTT were added to the buffers 
just before use. The viscous nuclear lysate was centrifuged at 35,000 rpm 
for 60 rain in a Beckman type 50.2 T1 rotor (Beckman Instruments, Inc., 
Fullerton, CA). The supernatant was used immediately or stored at -70~ 
without performing the dialysis step. Final protein concentration was be- 
tween 8 and  10 mg/ml  -l. 
Purification of Nuclear Cap Binding Protein  from 
HeLa Nuclei 
Buffer I contained 10% (vol/vol) glycerol, 20 m_M Hepes, pH 7.9, and 0.2 
mM EDTA. Buffer H contained 10% (vol/vol) glycerol, 20 mM Hepes, pH 
7.9, 0.5 M NaC1, 1% Triton X-100, 1 mM EDTA, 0.5 mM DTT, 0.1 mM 
PMSF, 0.5% (vol/vol) thiodyglycol and 1% (vol/vol) Trasylol. All columns 
were run at 4~  Protein concentrations were determined using the Bio-Rad 
protein  assay (Bio-Rad Laboratories,  Cambridge,  MA)  with BSA as  a 
standard. 
HeLa nuclear extract was adjusted to 4 M NaC1, centrifuged for 30 rain 
at 10,000 rpm in a Sorvall SS-34 (Sorvail Instruments, Newton, CT) rotor 
and  applied  to  a  Pbenyl-Sepharose  CL-4B  column  of  18  ￿  2  cm, 
equilibrated in buffer I plus 4 M NaCI. The column was washed with several 
volumes of buffer I containing 4 M NaC1 and eluted in a stepwise manner 
with buffer I containing 2.5 M, 1 M, and 50 mM NaC1, respectively. Elu- 
tion was performed at 0.8 mi rain  -I and monitored  at 280 nm.  The cap 
binding activity eluted during the 1 M NaCI step. The 1 M NaC1 eluate was 
diluted threefold with buffer I, adjusted to 50% saturation with solid ammo- 
nium sulphate and stirred 30 rain on ice. After centrifugation for 30 rain 
at 10,000 rpm (Sorvall HB-4 rotor) the precipitate was dissolved in buffer 
I containing 2.5 M NaC1. The suspension was applied to a Sephacryl S-300 
column of 60  x  2 cm, equilibrated in buffer I plus 2.5 M NaCl.  Eiution 
was performed with the same buffer at 0.3 mi rain  -~. 2-mi fractions were 
assayed, pooled, and dialyzed for 1 h against 1 1 of buffer II. Dialysis was 
continued in the same buffer containing  15% (wt/vol) PEG 4000 until the 
sample volume was reduced to •5  ml. 
A~inity Chromatography 
In vitro synthesized, capped or uncapped RNAs ('~0.7 rag) with a specific 
activity of 104 cpm/zg  -l were coupled to 1.2 g of CNBr-activated Sepha- 
rose 4B according to the recommendations of  the manufacturer (Pharmacia 
Fine Chemicals). Coupling efficiency was determined by comparing the in- 
put RNA solution with the remaining  free RNA  in the supernatant  and 
washes. Coupling efficiency was '~75%. The resin was prewashed with 6 
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mTGpppG is concentration dependent. Oocytes were injected with 
a U1AD gene.  After 16 h oL-32P GTP was  injected  into the same 
oocytes together with either HzO (lanes  1-3),  10 mM mTGpppG 
(lanes  4-6) or 50 mM mTGpppG (lanes  7-9). 4 h later RNA was 
extracted from 10 pooled nuclear or cytoplasmic fractions (denoted 
Nand Con the top of the figure) or from 10 total oocytes (denoted 
Ton the top of the figure). One oocyte equivalent of RNA was ana- 
lyzed on an 8 % denaturing polyacrylamide gel. 
vols of  buffer  II and rotated for 3 h at 4~  with the PEG-concentrated  frac- 
tions obtained from the Sephacryl column in the presence of 2 #g/ml  -~ 
pepstatin A, 300 #g/ml  -l benzamidine and 35 #g/ml  -l of yeast RNA. The 
mixture was then poured into a  10 ml Bio-Rad Poly-Prep column and 
washed with six column volumes of buffer II. Elution was performed with 
buffer I containing 0.2% SDS, 1 mM EDTA, and 0.1 M NaCI. Fractions 
of 0.5 ml were collected in Eppendorf tubes containing 0.2 ml of equil- 
ibrated phenol. After collecting the equivalent of three column volumes, 
fractions were phenol  extracted. Aqueous  phases were  discarded and phenol 
phases were extracted with 5 vols of ether saturated in water. The organic 
phases were discarded and the residual aqueous phases were reextracted 
with ether and concentrated on a Speed Vac concentrator (Savant Instru- 
ments, Fullerton, CA). Samples were resuspended in protein gel sample 
buffer and analyzed on 10% SDS-polyacrylamide  gels. 
Results 
Nuclear Export of U1 snRNA Is Not 
Inhibited by the Same Set of  Cap Analogs That Inhibit 
Protein Synthesis 
After  transcription,  U1  snRNAs  are  exported  into  the 
cytoplasm  where  they  assemble  into  U1  snRNPs  before 
migrating back into the nucleus.  This  remigrafion requires 
the presence of a functional Sm binding site, the region rec- 
ognized by the common U  snRNP proteins (Hamm et al., 
1990). A U1 mutant unable to bind these proteins will there- 
fore accumulate in the cytoplasm, being unable to move back 
to the nucleus.  Recently, however, it has been shown that in 
the presence of the cap analog mTG(5')ppp(5')G, such a mu- 
tant  is  localized  predominantly  in  the  nucleus  since  the 
dinucleotide  inhibits  the  nuclear  exit  of  U1  transcripts 
(Hamm and Mattaj,  1990). Fig.  1 shows that this inhibition 
is concentration dependent. Genes encoding a U1 mutant in 
which the Sm binding site was replaced by an artificial se- 
quence (U1AD) were injected into the nuclei of oocytes. 16 h 
later (ct-3~P)GTP was injected either alone or together with 
mTGpppG. After a further 4-h incubation oocytes were dis- 
sected, and RNA from nuclear and cytoplasmic fractions or 
from total oocytes was analyzed. In control oocytes (Fig.  1, 
lanes 1-3) U1AD transcripts were present almost exclusively 
in the cytoplasmic fraction (lane 2).  In contrast,  in oocytes 
injected with 50 mM mTGpppG (Fig.  1, lanes 7-9), ~50% 
of U1AD transcripts were retained in the nucleus (lane 9). 
The inhibitory effect is concentration dependent, since it was 
much reduced when a  10 mM solution was injected (Fig.  1, 
lanes 4-6) and was partial  when solutions of intermediate 
concentration were used (data not shown). Note that injec- 
tion of the dinucleotide reduces the overall level of transcrip- 
tion by a factor of  roughly twofold compared with control oo- 
cytes. This effect was observed with all nucleotides tested, 
independent of their effect on transport (see below), and can- 
not therefore be the cause of the transport inhibition. 
Together with previous results (Hamm and Mattaj,  1990) 
this  suggests  that a  trans-acting  factor which binds to the 
Figure  2.  Inhibition  of  U1 
snRNA  nuclear  export  by 
different cap analogs.  Oocytes 
were injected with U1AD gene 
followed  by  tx-32P GTP  and 
either  H20  (lanes  1-3) or 
50  mM  of the  following  di- 
nucleotides:  GpppG  (lanes 
4-6), mTGpppG (lanes  7-9), 
EtVGpppG (lanes 10-12) and 
m2.VGpppG  (lanes  13-15). 
RNA was analyzed as in Fig. 
1. Bands indicated  by dots on 
the  edge  of  the  figure  cor- 
respond to endogenous tran- 
scripts  and were used as con- 
trois  for recovery of nuclear 
RNAs. 
lzaurralde et al. Cap-dependent  RNA Nuclear Export  1289 Figure 3. A CBP is present in HeLa nuclear extracts. An electrophoretic mobility retardation assay was carried out using a radioactively 
labeled RNA probe of 77 nucleotides with either an inverted 7-methyl guanosine cap structure or a triphosphate Y-end. Yeast RNA or 
the same 77-nucleotide-long (unlabeled) RNA with a 5'-triphosphate were used as competitors. HeLa nuclear extract (0.3 ~1) was added 
to the RNA mixtures and incubated for 30 min at 25~  After the incubation period,  samples were loaded onto a 6% polyacrylamide 
gel in TBE buffer. The star indicates the altered mobility of the capped RNA due to a CBP present in the nuclear extract. The filled circles 
indicate two major shifts due to unidentified RNA binding proteins. (A) Increasing amounts of competitor yeast RNA were tested as indi- 
cated above the lanes. (Lanes 1-7) Gel retardation assay using a capped RNA probe; (lanes 8-14) gel retardation assay using an uncapped 
RNA probe; (lanes I and 8 ) free RNAs. (B) Effect  of  unlabeled RNA as competitor. HeLa nuclear extract was added to mixtures containing 
capped or uncapped labeled 77-nucleotide RNA (lanes 1-4 or 5-8, respectively) in the presence of 8/~g of yeast RNA and 0.2/~g (lanes 
3 and 7) or 1/~g (lanes 4 and 8) of  unlabeled uncapped 77-nucleotide RNA. (Lanes I and 5) Free RNAs; (lanes 2 and 6) no unlabeled RNA. 
monomethyl cap structure is involved in U1 snRNA export. 
Several nuclear and cytoplasmic CBPs have been described 
in extracts of  mammalian, plant and yeast cells (see introduc- 
tion). To investigate if the CBA involved in nuclear transport 
might be related to the translation initiation factor elF-4E 
(reviewed by  Shatkin,  1985;  Rhoads,  1988;  Sonenberg, 
1988), we tested a series of cap analogs, whose affinity for 
human  elF-4E has  previously been determined,  for their 
ability to inhibit nuclear export of U1AD transcripts in vivo. 
In  initial  experiments  five  dinucleotide  cap  analogs, 
m7GpppG,  EtTGpppG, m2.TGpppG, m2.2,7GpppG and GpppG, 
and the mononucleotide m2,TGMP, were tested. In oocytes 
injected only with (t~-z:P)GTP (Fig.  2,  lanes 1-3)  U1AD 
transcripts were present almost exclusively in the cytoplas- 
mic fraction (Fig. 2, lane 2). In contrast, in oocytes injected 
either with 50 mM mTGpppG (Fig. 2, lanes 7-9) or 50 mM 
EtTGpppG (Fig. 2, lanes 10-12), >60% of U1AD transcripts 
were retained in the nucleus. Injection of either m~.TGpppG 
(Fig.  2,  lanes  13-15)  or m:,2.TGpppG (data not shown) at 
50 mM did not affect the cellular distribution of U1AD tran- 
scripts which accumulate, as in the control, exclusively in 
the cytoplasm. The dinucleofide GpppG seems to be slightly 
more efficient as competitor than the dimethyldinucleotide 
since in its presence a  small fraction of U1AD transcripts 
were retained in the nucleus (Fig. 2, lanes 4-6). It is pos- 
sible that this inhibitory effect is due to a partial methyla- 
tion of the dinucleotide after injection. The mononucleotide 
m2.TGMP did not inhibit nuclear export (data not shown). 
In summary, the competition experiments show that, in ad- 
dition to 7-methyl diguanosine triphosphate,  the only N-7 
substituted  cap  analog  able  to  inhibit  nuclear  export  of 
UlsnRNA transcripts was "/-ethyl diguanosine triphosphate. 
The  dinucleotide  m~,7GpppG was  not  able  to  inhibit  U1 
snRNA  export  whereas  it  has  been  shown  to  be  more 
efficient than EtTGpppG in binding to elF-4E and inhibiting 
protein synthesis (Carberry et al.,  1990; Darzynkiewicz et 
al.,  1988,  1989).  In  addition,  neither  m2.7GMP or  other 
mononucleotides tested inhibited nuclear exit of U1AD tran- 
scripts (data not shown). These results demonstrate that the 
CBA involved in RNA export does not exhibit the same bind- 
ing specificity as elF-4E. 
Identification of  a CBP in HeLa Nuclear Extracts 
The results described in the above section suggest that the 
CBA involved in U1 snRNA export is not eIF-4E. We there- 
fore decided to search for CBPs whose binding specificity 
for cap analogs correlated with the ability of the analogs to 
inhibit RNA transport. A  simple assay that has previously 
been used to detect complexes between RNA and various 
specific RNA-binding proteins (Leibold and Munroe, 1988; 
Query et al.,  1989;  Scherly et al.,  1989) including CBPs 
(Ohno et al.,  1990) is native gel electrophoresis. Nuclear 
or whole cell extracts prepared from different sources were 
assayed  for  CBPs  using  this  assay.  For  the  analysis,  a 
32P-labeled RNA 77-nucleotides in length with either a tri- 
phosphate or a mTGpppG Y-end was incubated with nuclear 
extract and resulting complexes were separated by nondena- 
turing polyacrylamide gel electrophoresis. Yeast RNA was 
included in the reactions to minimize nonspecific interac- 
tions between proteins and the probe RNA. 
Of the  extracts  tested,  including  nuclear  extracts  from 
mammalian and frog cultured cells and whole cell extracts 
from Xenopus oocytes or Saccharom)~:es cerevisiae, the clear- 
est positive results were obtained using nuclear extracts of 
HeLa cells,  where an abundant  specific complex was ob- 
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A, lanes 2-7; see also Ohno et al., 1990). This complex was 
absent when the uncapped control RNA was used (Fig. 3 A, 
lanes 9-14). Two additional major complexes were observed 
for both RNAs (indicated by dots) and were competed to 
different extents by increasing concentrations of yeast RNA. 
These bands were consistently stronger for the uncapped 
probe, suggesting that either the cap structure itself, or a fac- 
tor binding to it, reduced the binding to these other proteins. 
In the experiment shown in Fig. 3 B an electrophoretic mo- 
bility retardation assay was carried out in which the same 77 
nucleotide RNA used as a probe, but prepared in the absence 
of  either radioactive label or cap analogs, was used as a com- 
petitor in addition to yeast RNA. The use of this additional 
competitor allowed exclusive detection of the complex due 
to the CBP in the extract (see lanes 3, 4, 7, and 8). The ex- 
periments described in the following sections were carried 
out in the same conditions as Fig. 3 B, lanes 4 and 8.  The 
CBP that gave rise to the retarded complex was also detected 
in S-100 cytoplasmic extracts, although the specific activity 
was at least five times lower than in nuclear extracts (data 
not shown). Whether this cytoplasmic activity reflects the 
cellular distribution of the protein in vivo or results from nu- 
clear leakage during cell homogenization is not yet estab- 
lished. 
The buffer conditions for optimal complex formation were 
analyzed. The CBP does not require magnesium or ATP for 
binding and is insensitive to salt concentration up to 1 M 
KC1. Binding is not inhibited by nonionic detergents such as 
NP-40, Tween 20, Triton X-100, or digitonin up to 2 %. How- 
ever, ionic detergents such as SDS or sarkosyl inhibited bind- 
ing at concentrations as low as 0.05 % even in the presence 
of an excess of nonionic detergent. All of the properties of 
the CBP described thus far were similar to those reported by 
Ohno et al. (1990),  suggesting that we were most likely de- 
tecting the protein investigated by those authors (see below). 
The Binding Specificity of  HeLa Nuclear CBP 
The specificity of  the CBP observed in HeLa nuclear extracts 
was investigated by testing different cap analogs for their 
ability to compete for its binding to a capped RNA probe. 
Native gel electophoresis was carried out under conditions 
where only the CBP was observed (see Fig. 3 B, lane 4). In- 
creasing amounts of different cap analogs were added to the 
reaction mixtures and their effects on cap-dependent com- 
plex formation assayed. Fig. 4 A shows a competition experi- 
ment with the cap analogs mTGpppG (Fig.  4 A, lanes 3-7) 
and Et7GpppG (Fig. 4 A, lanes 10-14). These dinucleotides 
were able to inhibit 50% of the binding at concentrations be- 
tween 5 and 10/zM. Dinucleotides methylated in position 2 
in addition to position 7 were "~l,000-fold less efficient as 
competitors than the analogs substituted exclusively in posi- 
tion 7. Fig. 4 B shows that the m~,7GpppG (Fig. 4 B, lanes 
10-13) and m2.2,TGpppG (Fig. 4 B, lanes 15-18) were able 
to inhibit 50 % of the shift at concentrations between 2.5 and 
5  mM  whereas  the  same  inhibition  was  observed  with 
m7GpppG  at 5/~M (Fig. 4 B,  lane 3).  The unmethylated 
dinucleotide GpppG was a more efficient competitor than the 
di- or tri-methylated dinucleotides since it inhibited complex 
formation to the same extent at a fivefold lower concentration 
(Fig. 4 B, lanes 5-8). Competition experiments were also 
performed with mononucleotides methylated at position 7 
(Fig. 4 C). The mononucleotide di- and tri-phosphates were 
able to inhibit >50% of  the shift at 1 mM concentration (Fig. 
4 C, lanes 10 and 13, respectively) while mTGMP inhibited 
more weakly and GMP not at all at this concentration (Fig. 
4  C, lanes 7 and 4, respectively). 
These results demonstrated that the CBP found in HeLa 
cell nuclear extract exhibited the same cap analog recogni- 
tion specificity as the CBA involved in U1 snRNA nuclear 
export, since the only dinucleotides shown to efficiently in- 
hibit CBP binding and U1 RNA export were m7GpppG and 
EtTGpppG. Furthermore, the observation that the dinucleo- 
tides tested in Fig. 4 B and the mononucleotides tested in 
Fig. 4 C were inefficient competitors strengthens the argu- 
ment that the activity is different from elF-4E. The concen- 
tration dependence for the inhibition of CBP binding in vitro 
was much lower than for transport inhibition in vivo. How- 
ever, we have no way to measure the effective  in vivo concen- 
tration of the injected nucleotides. 
Purification of CBP  from HeLa Nuclear Extracts 
The correlation between the results obtained by competition 
of CBP binding in vitro and of U1 snRNA nuclear export in 
vivo with different cap analogs suggest that the CBP present 
in HeLa nuclear extracts could be involved in nuclear export. 
To obtain more definitive information on the identity of the 
CBP, and in particular whether it was identical to the CBP 
previously described (Ohno et al.  1990),  we undertook its 
purification. 
Initial attempts to duplicate the purification procedure of 
Ohno et al. (1990) resulted in disappointingly low recovery 
efficiencies, and the initial two chromatographic steps of 
their procedure were therefore changed as follows. The CBP 
was purified from HeLa nuclear extracts by column chroma- 
tography using  sequentially Phenyl-Sepharose,  Sephacryl 
S-300 and affinity chromatography (for details, see Mate- 
rials and Methods). The activity was monitored by the native 
gel electrophoresis assay described above.  Several experi- 
ments showed that •90%  of  the detectable CBP eluted in the 
1 M  NaCI elution step of the Phenyl-Sepharose column. 
Next, this fraction was loaded onto a Sephacryl S-300 col- 
umn after concentration by ammonium sulfate precipitation. 
At high salt, about *60% of the input CBP eluted from the 
Sephacryl column between the 100- and 66-kD molecular 
mass markers, corresponding to Calf  Intestine Alkaline Phos- 
phatase and BSA, respectively (data not shown). Additional 
activity was found consistently between the 466- (Ferritin) 
and  100-kD  molecular mass markers,  but these fractions 
were discarded. Note that at salt concentrations below 1 M 
NaC1 the CBP was found predominantly in the exclusion vol- 
ume of the Sephacryl column. The nature of the high molec- 
ular mass complexes formed at lower salt concentration was 
not investigated further. 
Fig. 5 A shows the pattern of proteins in the active frac- 
tions eluted from the Phenyl Sepharose and Sephacryl col- 
umns (lanes 3  and 4,  respectively) compared to proteins 
from nuclear extract (Fig. 5 A, lane 2). In parallel, quantita- 
tion of specific cap binding after the two first steps of purifi- 
cation was performed. Fig. 5 B shows an assay of the active 
fractions obtained after Phenyl Sepharose or Sephacryl col- 
umns (Fig. 5 B, lanes 3 and 4, respectively) compared with 
the total extract (Fig. 5 B, lane 2). 
The CBP-containing fractions eluted from the Sephacryl 
column were dialyzed to reduce the salt concentration, con- 
centrated, and loaded onto an affinity  resin made by coupling 
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binding by different analogs. 
A capped RNA probe was in- 
cubated with 0.3 ~1 of HeLa 
nuclear extract in the presence 
of 8/ag of  yeast RNA and 1/zg 
of  unlabeled  uncapped  77 
nucleotide RNA as competi- 
tors.  Increasing  amounts  of 
different  cap  analogs were 
added to the reaction mixtures 
which were processed as de- 
scribed in Fig.  3.  Final con- 
centrations of cap analogs in 
the binding reactions are indi- 
cated above the lanes. Lane I 
in all panels  shows the  free 
RNA.  The star indicates the 
altered mobility of the capped 
RNA  due  to  the  CBP. (A) 
Competition  with  the  dinu- 
cleotides  mTGpppG (lanes 
3-7)  and  EtTGpppG (lanes 
10--14). (Lanes 2, 8, and 9) No dinucleotides. (B) Competition with the dinucleotides mTGpppG  (lane 3), GpppG (lanes 5-8), m2.TGpppG 
(lanes 10-13) and mZ.Z.TGpppG  (lanes 15-18). (Lanes 2, 4, 9, and 14) No dinucleotide. (C) Competition with the following mononucleo- 
tides: GMP (lanes 3 and 4), mTGMP (lanes 6 and 7), mTGDP (lanes 9 and I0), and mTGTP (lanes 12 and 13).  (Lanes 2, 5, 8, and 11) 
No nucleotide. 
the capped 77 nucleotide RNA used for the previous assays 
to  a  Sepharose support.  After extensive washes,  proteins 
bound to the column were eluted with 0.2 % SDS. After elec- 
trophoresis in SDS-polyacrylamide gels and silver staining 
a major 80-kD band was observed in the SDS eluted frac- 
tions (indicated by a filled circle in Fig. 5 A, lane 5). This 
band was absent when an affinity column made with un- 
capped 77-nucleotide-long RNA was used (data not shown). 
Quantitation of the activity eluted from the affinity column 
was not possible since after SDS treatment the protein could 
not be renatured. However, by comparing the binding activ- 
ity present in the input, flowthrough, and wash fractions, we 
calculated  that  ,,080%  of the  CBP  bound  to  the  affinity 
column. Assuming that the CBP is efficiently  eluted by SDS- 
containing  buffer,  we  can  estimate  that  the  protein  was 
purified at least 4,000-fold. Elution of the affinity column 
with urea (4 M) or salt (4 M NaC1) allowed recovery of the 
binding  activity.  However, neither of these methods gave 
efficient elution and the activity spread over several column 
volumes. Fig.  5  C shows the elution profile of the affinity 
column when 4  M  urea was used for elution. The activity 
was present in several fractions (Fig. 5 C, lanes 4 to 10) that 
represented 4 column volumes. The sample in Fig. 5 C, lane 
2 is equivalent to that in Fig. 5 B, lane 4. The active fractions 
were pooled and an amount equivalent to a single fraction 
was compared with the fraction in which the activity was ab- 
sent (shown in Fig.  5  C, lane 3) by SDS-PAGE (Fig. 5 D, 
lanes I  and 2, respectively). Activity in the native gel elec- 
trophoresis assay correlated with the presence of the 80-kD 
band on a protein gel (Fig. 5 D, lane 1 ). This protein was 
absent in the fraction which was inactive in complex forma- 
tion (Fig. 5 D, lane 2). Proteins observed between the 45- 
The Journal of Cell Biology, Volume 118,  1992  1292 Figure 5. Purification of CBP from HeLa nuclear extracts. (A) HeLa nuclear extract was fractionated by column chromatography  using 
sequentially Phenyl-Sepharose, Sephacryl S-300 and capped RNA affinity columns. Active fractions eluted from these columns were ana- 
lyzed by SDS-gel electrophoresis.  The gel was stained with silver nitrate. (Lane 1 ) Molecular mass markers (M); (lane 2) HeLa nuclear 
extract (E); 0ane 3) 1.0 M NaC1 eluate from the Phenyl-Sepharose column (P); (lane 4) pool of active fractions eluted from the Sephacryl 
S-300 column (S);  and (lane 5) pool of SDS-eluted fractions  from the Affinity column (A). Lanes 2, 3, and 4 were loaded with 35/~g 
of protein,  lane 5 with about 25 ng of the CBP. The filled circle on the right side of the figure indicates the position of the 80-kD CBP. 
(B) Hela nuclear extracts and active fractions eluted either from the Phenyl Sepharose or Sephacryl columns were tested by electrophoretic 
mobility retardation  assay under the conditions used in Fig. 3 B, lane 4.  (Lane 1) Free RNA; (lane 2) HeLa nuclear extract (E); (lane 
3) 1.0 M NaC1 eluate from the Phenyl-Sepharose column (P); and 0ane 4) pool of active fractions eluted from the Sephacryl S-300 column 
(S).  Lanes 2 to 4 contain 0.8/~g of total protein.  The star shows the position of CBP-RNA complexes. (C) A HeLa nuclear extract was 
fractionated as described in A, except that the affinity column was eluted with 4 M urea instead of 0.2 % SDS. 1-ml fractions were collected 
and tested as in B. (Lane 1) Free RNA; (lane 2) input; and (lanes 3-14) urea eluted fractions. (D) Active fractions shown in C lanes 4-10 
were pooled and precipitated.  An amount equivalent to a single fraction was analyzed on a protein gel in parallel with the inactive fraction 
shown in C, lane 3. (Lane 1 ) Pool of active fractions;  (lane 2) inactive fraction; and (lane 3) molecular mass markers. The gel was stained 
with silver nitrate.  The filled circle indicates the position  of the 80-kD CBP. 
and 66-kD molecular mass markers were present in all frac- 
tions and their presence did not correlate with CBP activity. 
Together, the above results strongly indicate that the CBP in 
HeLa nuclear extract is the 80-kD protein. The apparent mo- 
lecular mass of the purified protein is identical to that of the 
CBP purified by Ohno et al. (1990), confirming that the two 
proteins are almost certainly the same. 
Discussion 
We have described the purification of a CBP from HeLa nu- 
clear extracts. The specificity of this protein for cap analogs is 
different from that of the best characterized cap binding pro- 
tein, the translational initiation factor elF-4E.  Equilibrium 
binding constants for complexes of elF-4E with N-7 alkyl- 
substituted cap analogs have been determined and vary over 
a  roughly  10-fold  range  as  follows:  mTGTP =  mTGpppG 
>  m~.7GMP  >  m2.TGpppG  >  m7GMP  >  EtTGpppG  > 
m~,2.TGpppG (Carberry et  al.,  1989,  1990).  The  CBP de- 
scribed in this study binds efficiently only to m7GpppG and 
EtTGpppG.  The affinity for other dinucleotides  is  at least 
1,000-fold lower. In addition, while elF-4E binds to N-7 sub- 
stituted guanosine or diguanosine triphosphate with similar 
equilibrium  binding  constants,  the  nuclear  CBP  binds  to 
m7GpppG at least 100-fold more efficiently than to m7GTP. 
These results suggest that the nuclear CBP is not elF-4E. 
We have also shown that the relative affinity of cap analogs 
for the HeLa CBP correlates with their efficacy as inhibitors 
of the nuclear export of U1 snRNA in Xenopus oocytes, since 
the only nucleotides which were able to inhibit U1  snRNA 
export  were  mTGpppG and  Et7GpppG.  In  summary,  our 
results demonstrate that the CBA involved in RNA export 
and the nuclear CBP exhibit the same binding specificity for 
the cap analogs tested, but more direct biochemical evidence 
is required to show that the same CBP is also present in the 
nuclei of Xenopus oocytes. 
In addition to elF-4E,  several other CBPs have been de- 
scribed. Three, with apparent molecular masses of 120,  89, 
and 80 kD have been identified by photoaffinity labeling in 
HeLa  nuclear  extracts  (Patzelt  et  al.,  1983).  Rozen  and 
Sonenberg (1987)  identified two additional nuclear CBPs of 
115 and 20 kD by UV cross-linking.  Finally, a  CBP of 80 
kD has been detected in HeLa nuclear extracts by means of 
an electrophoretic mobility shift assay (Ohno et al.,  1990). 
Based on most of the reported properties of this protein, e.g., 
the apparent molecular mass, the  resistance of binding  to 
high salt and to competition with GpppG and m2,2.TGpppG, 
it seems likely that it is the same as the protein analyzed here, 
although we saw similar inhibition of binding in competition 
experiments with either mTGDP or mTGTP (Fig. 4  C) while 
the complexes observed by Ohno et al. (1990) were insensi- 
tive to competition with m7GDP. 
In microinjection experiments in Xenopus oocytes, it has 
been shown that the cap structure of a pre-mRNA can have 
an effect on both the efficiency of splicing of an intron in the 
pre-mRNA and on the selection of cap-proximal versus cap- 
distal introns (Inoue et al., 1989). Furthermore, earlier work 
in which cap analogues were used as inhibitors of in vitro 
splicing (Konarska et al., 1984; Edery and Sonenberg, 1985) 
or of splicing complex formation (Patzelt et al.,  1987) had 
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mRNA processing.  On this basis, but without more direct 
evidence, Ohno et al., (1990) proposed that the 80-kD CBP 
which they identified might be involved in splicing. The re- 
suits presented in this paper suggest a different possibility, 
that the 80-kD CBP may play a role in the export of capped 
RNAs from the nucleus. It is of course possible that the pro- 
tein  might be bifunctional.  In addition,  the  other nuclear 
CBPs mentioned above might have  roles in either splicing 
or  RNA  transport.  Moreover,  it may  be that,  while both 
RNA polymerase II-transcribed U snRNAs and mRNAs re- 
quire cap structures  for export from the nucleus (Hamm and 
Mattaj,  1990),  that the CBP mediating export of these two 
classes of RNA could be different. 
It is likely that transport  out of the nucleus will involve 
RNPs rather than naked RNAs. The very large Balbiani ring 
mRNAs, made in Chironomus tentans salivary  glands, have 
been convincingly shown to be associated with proteins on 
both sides of the nuclear membrane during export (Mehlin 
et al., 1991).  While our data (Hamm and Mattaj,  1990; this 
study)  show that cap recognition by a CBA is required for 
export, they do not rule out the possibility that other RNA 
binding proteins might also be required for export of either 
specific pol II RNAs or of RNAs in general. 
Recently, suggestive evidence for a role of the hnRNP A1 
protein in mRNA export has been provided (Pifiol-Roma and 
Dreyfuss,  1992). mRNA precursors associate in the nucleus 
with the  abundant  hnRNP  proteins to  form hnRNPs  (re- 
viewed by Dreyfuss,  1986).  Until recently, it was believed 
that these proteins dissociate from the RNA before or during 
transport,  but the new data suggest that this may not be the 
case for all the hnRNP proteins. In particular,  it was shown 
that hnRNP A1 protein shuttles between the nucleus and cyto- 
plasm during  interphase.  Cross-linking  experiments  dem- 
onstrated that the cytoplasmic pool of A1  protein was as- 
sociated  with poly  (A) § RNA  (Pifiol-Roma and Dreyfuss, 
1992).  This suggests that mRNA may be exported from the 
nucleus in association with the A1  protein, and potentially 
also other shuttling  hnRNP proteins. 
Proteins involved in the export of other specific RNAs have 
been  described.  Nuclear  export  of 5S  RNA  is  probably 
mediated by either the L5 ribosomal protein, TFIIIA, or an- 
other protein  with similar RNA  binding  specificity,  since 
mutated 5S RNAs unable to interact  with these proteins re- 
main in the nucleus (Guddat et al., 1990). The influenza vi- 
rus matrix protein M1 is required for nuclear export of viral 
RNPs (Martin  and Helenius,  1991).  In the absence of M1, 
the RNPs accumulate in the nucleus. Finally, the Human Im- 
munodeficiency Virus (HIV) Rev protein is required for ac- 
cumulation of unspliced late viral RNAs in the cytoplasm 
(reviewed by Chang and Sharp,  1990) and the suggestion has 
been made that it might directly stimulate the nuclear export 
of these RNAs.  However, evidence has been presented that 
the mode of action of this protein is to dislodge viral RNAs 
from spliceosome components which anchor them to the nu- 
cleus,  rather  than to stimulate export directly (Chang  and 
Sharp,  1989). 
Definite proof that any  of the above-mentioned proteins 
has a role in mRNA export is lacking and, as yet, there is 
no indication of how any protein might mediate RNA export 
at the molecular level. Our results  suggest that the CBP ex- 
amined here may form an essential part of RNP export sub- 
strates  formed on  U  snRNAs  and  possibly  other  pol  II- 
transcribed RNAs, the first such component to be identified. 
Further characterization of the nuclear CBP will allow us to 
establish its role more definitively. 
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